| Revenue growth | 9.5% YoY reaching ₹33.04 Cr in FY26. |
|---|---|
| Margins | EBITDA margin improved slightly to 31.63% from 30.76% YoY. |
| Demand visibility | Strong, driven by rising chronic diseases and advanced imaging needs. |
| Management confidence | High, following successful NSE Emerge listing in Dec 2025. |
Growth
Total Income grew from ₹30.18 Cr (FY25) to ₹33.04 Cr (FY26); Net Profit remained stable at ₹4.87 Cr.
Outlook
Plans to triple network size over 3 years, expanding into Pune, Nashik, and Akola with 6-7 new centres.
Risks
High capital intensity, competition in pathology, and geographic concentration in Maharashtra.
Earnings Call filed with NSE, NSE: INVICTA. Summary written with AI assistance from the document.
Invicta Diagnostic Ltd: key numbers
- Share price
- ₹66.50
- Market cap
- ₹83.60 Cr
- Revenue (annual)
- ₹32.35 Cr
- Net profit (annual)
- ₹4.91 Cr
- P/E (TTM)
- 17.0×Sector 53.1×
- Promoter holding
- 66.70%
- FII holding
- 4.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Invicta Diagnostic Ltd
All →Invicta Diagnostic Management Change
Invicta Diagnostic Limited reported changes to its leadership and audit team, including a director's re-appointment, a designation change, and a new secretarial auditor.
Invicta Diagnostic Annual General Meeting
Invicta Diagnostic Limited conducted its 3rd Annual General Meeting on September 19, 2026. The proceedings detailed company operations and future financial targets.
Invicta Diagnostic Board Meeting Outcome
Board approved business outlook and forward-looking guidance for the 3rd AGM on 19 September 2026. Company targets consolidated revenue of ₹45–50 crore with ~25% EBITDA margin.
Invicta Diagnostic Capacity Expansion
Invicta's subsidiaries commenced operations at two diagnostic centres in Shegaon and Pune. Investment is Rs. 70 lakhs for CT scan and pathology services.
- diagnostic service centres
- 2 centres
Invicta Diagnostic Annual General Meeting
Invicta Diagnostic approved the notice for its 3rd Annual General Meeting scheduled for 19th September 2026, alongside adoption of financial reports and director appointments.
Invicta Diagnostic Merger & Restructuring Worth ₹0.01 Cr
Invicta Diagnostic Limited is selling its associate entity, MSCRIBEIT INFOTECH LLP, for a cash consideration of Rs. 50,000. The transaction is expected to conclude by March 2027.
- Value
- ₹0.01 Cr